These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

642 related items for PubMed ID: 25714871

  • 21. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P, Levidou G, Trigka EA, Prekete N, Karlou M, Thymara I, Sakellariou S, Fragkou P, Isaiadis D, Pavlopoulos P, Patsouris E, Saetta AA.
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [Abstract] [Full Text] [Related]

  • 22. PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer.
    Prenen H, De Schutter J, Jacobs B, De Roock W, Biesmans B, Claes B, Lambrechts D, Van Cutsem E, Tejpar S.
    Clin Cancer Res; 2009 May 01; 15(9):3184-8. PubMed ID: 19366826
    [Abstract] [Full Text] [Related]

  • 23. Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations.
    Ganesan P, Janku F, Naing A, Hong DS, Tsimberidou AM, Falchook GS, Wheler JJ, Piha-Paul SA, Fu S, Stepanek VM, Lee JJ, Luthra R, Overman MJ, Kopetz ES, Wolff RA, Kurzrock R.
    Mol Cancer Ther; 2013 Dec 01; 12(12):2857-63. PubMed ID: 24092809
    [Abstract] [Full Text] [Related]

  • 24. Frequent PIK3CA-activating mutations in hidradenoma papilliferums.
    Liau JY, Lan J, Hong JB, Tsai JH, Kuo KT, Chu CY, Sheen YS, Huang WC.
    Hum Pathol; 2016 Sep 01; 55():57-62. PubMed ID: 27184479
    [Abstract] [Full Text] [Related]

  • 25. Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.
    Deng L, Chen J, Zhong XR, Luo T, Wang YP, Huang HF, Yin LJ, Qiu Y, Bu H, Lv Q, Zheng H.
    PLoS One; 2015 Sep 01; 10(3):e0120511. PubMed ID: 25816324
    [Abstract] [Full Text] [Related]

  • 26. PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer--results from NCIC CTG/AGITG CO.17.
    Karapetis CS, Jonker D, Daneshmand M, Hanson JE, O'Callaghan CJ, Marginean C, Zalcberg JR, Simes J, Moore MJ, Tebbutt NC, Price TJ, Shapiro JD, Pavlakis N, Gibbs P, Van Hazel GA, Lee U, Haq R, Virk S, Tu D, Lorimer IA, NCIC Clinical Trials Group and the Australasian Gastro-Intestinal Trials Group.
    Clin Cancer Res; 2014 Feb 01; 20(3):744-53. PubMed ID: 24218517
    [Abstract] [Full Text] [Related]

  • 27. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
    Trigka EA, Levidou G, Saetta AA, Chatziandreou I, Tomos P, Thalassinos N, Anastasiou N, Spartalis E, Kavantzas N, Patsouris E, Korkolopoulou P.
    Oncol Rep; 2013 Aug 01; 30(2):623-36. PubMed ID: 23728071
    [Abstract] [Full Text] [Related]

  • 28. Analysis of PIK3CA Mutations and Activation Pathways in Triple Negative Breast Cancer.
    Cossu-Rocca P, Orrù S, Muroni MR, Sanges F, Sotgiu G, Ena S, Pira G, Murgia L, Manca A, Uras MG, Sarobba MG, Urru S, De Miglio MR.
    PLoS One; 2015 Aug 01; 10(11):e0141763. PubMed ID: 26540293
    [Abstract] [Full Text] [Related]

  • 29. Clinical Impact of Primary Tumor Location and RAS, BRAF V600E, and PIK3CA Mutations on Epidermal Growth Factor Receptor Inhibitor Efficacy as Third-line Chemotherapy for Metastatic Colorectal Cancer.
    Sato T, Osumi H, Shinozaki E, Ooki A, Shimozaki K, Kamiimabeppu D, Nakayama I, Wakatsuki T, Ogura M, Takahari D, Chin K, Yamaguchi K.
    Anticancer Res; 2021 Aug 01; 41(8):3905-3915. PubMed ID: 34281853
    [Abstract] [Full Text] [Related]

  • 30. Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study.
    Shinozaki E, Yoshino T, Yamazaki K, Muro K, Yamaguchi K, Nishina T, Yuki S, Shitara K, Bando H, Mimaki S, Nakai C, Matsushima K, Suzuki Y, Akagi K, Yamanaka T, Nomura S, Fujii S, Esumi H, Sugiyama M, Nishida N, Mizokami M, Koh Y, Abe Y, Ohtsu A, Tsuchihara K.
    Br J Cancer; 2017 Nov 07; 117(10):1450-1458. PubMed ID: 28972961
    [Abstract] [Full Text] [Related]

  • 31. Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation.
    Tie J, Gibbs P, Lipton L, Christie M, Jorissen RN, Burgess AW, Croxford M, Jones I, Langland R, Kosmider S, McKay D, Bollag G, Nolop K, Sieber OM, Desai J.
    Int J Cancer; 2011 May 01; 128(9):2075-84. PubMed ID: 20635392
    [Abstract] [Full Text] [Related]

  • 32. Molecular spectrum of KRAS, BRAF, and PIK3CA gene mutation: determination of frequency, distribution pattern in Indian colorectal carcinoma.
    Bisht S, Ahmad F, Sawaimoon S, Bhatia S, Das BR.
    Med Oncol; 2014 Sep 01; 31(9):124. PubMed ID: 25073438
    [Abstract] [Full Text] [Related]

  • 33. Overall Survival, BRAF, RAS, and MSI Status in Patients Who Underwent Cetuximab After Refractory Chemotherapy for Metastatic Colorectal Cancer.
    Santos FA, Reis RM, Barroti LC, Pereira AAL, Matsushita MM, de Carvalho AC, Datorre JG, Berardinelli GN, Araujo RLC.
    J Gastrointest Cancer; 2024 Mar 01; 55(1):344-354. PubMed ID: 37608030
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.
    Villaruz LC, Socinski MA, Abberbock S, Berry LD, Johnson BE, Kwiatkowski DJ, Iafrate AJ, Varella-Garcia M, Franklin WA, Camidge DR, Sequist LV, Haura EB, Ladanyi M, Kurland BF, Kugler K, Minna JD, Bunn PA, Kris MG.
    Cancer; 2015 Feb 01; 121(3):448-56. PubMed ID: 25273224
    [Abstract] [Full Text] [Related]

  • 36. Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers.
    Lee SY, Kim MJ, Jin G, Yoo SS, Park JY, Choi JE, Jeon HS, Cho S, Lee EB, Cha SI, Park TI, Kim CH, Jung TH, Park JY.
    J Thorac Oncol; 2010 Nov 01; 5(11):1734-40. PubMed ID: 20881644
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. [Molecular predictive markers of EGFR-targeted therapy in metastatic colorectal cancer].
    Fabian P, Berkovcová J.
    Cesk Patol; 2011 Oct 01; 47(4):154-8. PubMed ID: 22145213
    [Abstract] [Full Text] [Related]

  • 40. PIK3CA activating mutation in colorectal carcinoma: associations with molecular features and survival.
    Rosty C, Young JP, Walsh MD, Clendenning M, Sanderson K, Walters RJ, Parry S, Jenkins MA, Win AK, Southey MC, Hopper JL, Giles GG, Williamson EJ, English DR, Buchanan DD.
    PLoS One; 2013 Oct 01; 8(6):e65479. PubMed ID: 23785428
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 33.